



Director/PCA transaction initial notification

December 16, 2019

Released : December 16, 2019 17:25

RNS Number : 0553X

MaxCyte, Inc.

16 December 2019

MaxCyte, Inc.
("MaxCyte" or the "Company")

Director/PCA transaction initial notification

Gaithersburg, Maryland - 16 December 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company announces that John Johnston, Non-Executive Director, has transferred 17,041 ordinary shares of 0.1 pence each in the Company (Ordinary Shares) to his wife, Karin Johnston, a person closely associated (PCA). The transfer took place on 14 December 2019.

Following the transaction, the number of shares in which John Johnston has an interest remains unchanged at 120,583 Ordinary Shares.

This announcement, including the notification below, is made in accordance with the requirements of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	John Johnston

2	Reason for the notification	
a)	Position/status	Non-Executive Director and PDMR
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	MaxCyte, Inc.
b)	LEI	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary shares
b)	Identification Code	
c)	Nature of the transaction	Transfer of Ordinary Shares to spouse/PCA
d)	Price(s) and volume(s)	Price(s) Volume(s)
e)	Aggregated information	N/A
	- Aggregated volume	17,041
	- Price	
f)	Date of the transaction	14 December 2019
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

For further information, please contact:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

+1 301 944 1660

Ron Holtz, Chief Financial Officer

Nominated Adviser and Joint Corporate Broker

+44 (0)20 7886 2500

Panmure Gordon

Emma Earl
Freddy Crossley
Corporate Broking
James Stearns

Joint Corporate Broker

Numis Securities Limited

+44 (0)20 7260 1000

James Black
Duncan Monteith

Financial PR Adviser

Consilium Strategic Communications

+44 (0)203 709 5700

Mary-Jane Elliott
Chris Welsh
Sukaina Virji

maxcyte@consilium-comms.com

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including five commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than \$450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAXAKFADNFFF